David T. Broome

David T. Broome

Auto-generated profile, based on publicly available information

David T. Broome

Division of Metabolism, Endocrinology & Diabetes, University of Michigan, Ann Arbor, MI, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
DBDavid T Broome
David T Broome
KPKevin Pantalone
Kevin Pantalone
SKSangeeta Rao R Kashyap
Sangeeta Rao R Kashyap
LPLouis H Philipson
Louis H Philipson
Maturity-onset diabetes of the young, or MODY-monogenic diabetes, is a not-so-rare collection of inherited disorders of non-autoimmune diabetes mellitus that remains insufficiently diagnosed despite increasing awareness. These cases are important to efficiently and accurately diagnose, given the clinical implications of syndromic features, cost-effective treatment regimen, and the potential impact on multiple family members. Proper recognition of the clinical manifestations, family history, and cost-effective lab and genetic testing provide the diagnosis. All patients must undergo a thorough history, physical examination, multigenerational family history, lab evaluation (glycated hemoglobin A1c [HbA1c], glutamic acid decarboxylase antibodies [GADA], islet antigen 2 antibodies [IA-2A], and zinc transporter 8 [ZnT8] antibodies). The presence of clinical features with 3 (or more) negative antibodies may be indicative of MODY-monogenic diabetes, and is followed by genetic testing. Molecular genetic testing should be performed before attempting specific treatments in most cases. Additional testing that is helpful in determining the risk of MODY-monogenic diabetes is the MODY clinical risk calculator (>25% post-test probability in patients not treated with insulin within 6 months of diagnosis should trigger genetic testing) and 2-hour postprandial (after largest meal of day) urinary C-peptide to creatinine ratio (with a ≥0.2 nmol/mmol to distinguish HNF1A- or 4A-MODY from type 1 diabetes). Treatment, as well as monitoring for microvascular and macrovascular complications, is determined by the specific variant that is identified. In addition to the diagnostic approach, this article will highlight recent therapeutic advancements when patients no longer respond to first-line therapy (historically sulfonylurea treatment in many variants).Learning Objectives: Upon completion of this educational activity, participants should be able to:Target Audience: This continuing medical education activity should be of substantial interest to endocrinologists and all health care professionals who care for people with diabetes mellitus.

7 April 2020 in Diabetes Care
Verified
Journal Article
Open access
PDF file
DBDavid T. Broome
David T. Broome
ZTZehra Tekin
Zehra Tekin
KPKevin M. Pantalone
Kevin M. Pantalone
AMAdi E. Mehta
Adi E. Mehta
Maturity-onset diabetes of the young (MODY) is an inherited form of diabetes caused by a mutation in a single gene. The frequency of mutation carriers for HNF4A

1 February 2020 in Current Diabetes Reports
Verified
Journal Article
Closed access
PDF file
DBDavid T. Broome
David T. Broome
CHC. Beau Hilton
C. Beau Hilton
NMNeil Mehta
Neil Mehta

29 October 2020 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
DBDavid T Broome
David T Broome
RNRobert Naples
Robert Naples
RBRichard Bailey
Richard Bailey
ZTZehra Tekin
Zehra Tekin
MHMoska Hamidi
Moska Hamidi
MSMario Skugor
Mario Skugor
Context: Preoperative imaging is performed routinely to guide surgical management in primary hyperparathyroidism, but the optimal imaging modalities are debated. Objective: Our objectives were to evaluate which imaging modalities are associated with improved cure rate and higher concordance rates with intraoperative findings. A secondary aim was to determine whether additive imaging is associated with higher cure rate. Design, Setting, and Patients: This is a retrospective cohort review of 1485 adult patients during a 14-year period (2004-2017) at an academic tertiary referral center that presented for initial parathyroidectomy for de novo primary hyperparathyroidism. Main Outcome Measures: Surgical cure rate, concordance of imaging with operative findings, and imaging performance. Results: The overall cure rate was 94.1% (95% confidence interval, 0.93-0.95). Cure rate was significantly improved if sestamibi/single-photon emission computed tomography (SPECT) was concordant with operative findings (95.9% vs. 92.5%, P = 0.010). Adding a third imaging modality did not improve cure rate (1 imaging type 91.8% vs. 2 imaging types 94.4% vs. 3 imaging types 87.2%, P = 0.59). Despite having a low number of cases (n = 28), 4-dimensional (4D) CT scan outperformed (higher sensitivity, specificity, positive predictive value, negative predictive value) all imaging modalities in multiglandular disease and double adenomas, and sestamibi/SPECT in single adenomas. Conclusions: Preoperative ultrasound combined with sestamibi/SPECT were associated with the highest cure and concordance rates. If pathology was not found on ultrasound and sestamibi/SPECT, additional imaging did not improve the cure rate or concordance. 4D CT scan outperformed all imaging modalities in multiglandular disease and double adenomas, and sestamibi/SPECT in single adenomas, but these findings were underpowered.

10 March 2025 in Diabetes Care
Verified
Journal Article
Closed access
RMRasimcan Meral
Rasimcan Meral
MGMerve Celik Guler
Merve Celik Guler
DKDiarratou Kaba
Diarratou Kaba
JPJeevitha Prativadi
Jeevitha Prativadi
EFEric D. Frontera
Eric D. Frontera
EOElif A. Oral
Elif A. Oral
OBJECTIVE: Lipodystrophy encompasses a group of rare disorders associated with severe metabolic disease. These disorders are defined by abnormal fat distribution, with near-total (generalized lipodystrophy [GL]) or partial (partial lipodystrophy [PL]; e.g. familial partial lipodystrophy [FPLD]) absence of adipocyte mass, leading to a decreased ability to store lipids safely. Excess lipids are more likely to be stored in nonadipose tissues, which leads to the metabolic manifestations. We have recently shown that glucagon-like peptide-1 agonists are associated with metabolic improvements in FPLD. Here, we hypothesize that tirzepatide, a dual incretin, may also lead to metabolic improvement in patients with lipodystrophy. RESEARCH DESIGN AND METHODS: An observational cohort of patients with lipodystrophy who received tirzepatide clinically were tracked in the context of ongoing natural history studies. RESULTS: Seventeen patients received tirzepatide, 14 who had FPLD (aged 30–74 years; n = 12 female and 2 male). After a median 8.7 months of follow-up, the following were significantly reduced: BMI (median difference, −1.7; range, −5.9 to 0.9 kg/m2; P = 0.008), HbA1c (median difference, −1.1%; range −6.3% to −0.1%; P < 0.001), triglycerides (median difference, −65 mg/dL [−0.73 mmol/L]; range, −3,820 to 43 mg/dL [−43.2 to 0.49 mmol/L]; P = 0.003), and total daily insulin requirements (median difference, −109; range, −315 to 0 units/day; P = 0.002). Three additional patients with rarer forms of lipodystrophy, also with robust response to tirzepatide, are also discussed (atypical PL, n = 1; acquired GL; n = 2; aged 35–64 years; all female). Side effects were limited to benign gastrointestinal symptoms. CONCLUSIONS: Tirzepatide may be an effective treatment for patients with lipodystrophy.

1 August 2020 in Endocrine Connections
Verified
Journal Article
Open access
PDF file
DBDavid T Broome
David T Broome
GGGauri B Gadre
Gauri B Gadre
EFEhsan Fayazzadeh
Ehsan Fayazzadeh
JBJames Bena
James Bena
CNChristian Nasr
Christian Nasr
Objective:: To identify novel prognostic risk factors and compare them with other known prognostic risk factors in follicular-cell-derived thyroid carcinoma (FDTC) with distant metastases. Methods:: A retrospective review was conducted of adult patients with metastatic FDTC seen at a tertiary care center between January 1990 and December 2010. A 15-year Kaplan–Meier survival estimate was created for overall survival (OS) and cancer-specific survival (CSS). Hazard ratios (HR) and P values from Cox proportional hazard models were used with a 95% CI. Results:: There were 143 patients (60.1% male, 39.9% female), of whom 104 (72.7%) patients had papillary, 30 (21.0%) had follicular, 5 (3.5%) had poorly differentiated, and 4 (2.8%) had Hürthle cell cancers. Median length of follow-up was 80.0 months (range 1.0–564.0). The 15-year mortality rate was 32.2% and cancer-specific mortality was 25.2%, with OS and CSS having the same risk factors. Lung was the most common site of metastases in 53 patients (37.1%), and patients with pleural effusions had significantly lower CSS (HR = 5.21, CI = 1.79–15.12). Additional risk factors for a decreased CSS included: older age upon diagnosis (>45 years, HR = 4.15, CI = 1.43–12.02), multiple metastatic locations (HR = 3.75, CI = 1.32–10.67), and incomplete/unknown tumor resection (HR = 2.35, CI = 1.18–4.67). Conclusion:: This study is the first to demonstrate that pleural effusion is a poor prognostic sign in patients with FDTC with distant metastases and compare this risk with other accepted prognostic variables.